EASL Congress 2026: key results and trends

SMT+PE-A5% significantly increased 90-day OS compared to SMT (Hazard Ratio [HR] [95% CI] = 0.65 [0.45, 0.94]; p = 0.021).

LNF/RTV+Peg patients demonstrated ≥ 2 log HDV RNA reduction at a median time of 8.3 weeks (95% CI: 8.1-12.1) compared to 28.3 weeks (95% CI: 16.3-48.1) for Peg monotherapy using Kaplan Meier estimates.

Biochemical response was achieved in 56.7% with saroglitazar compared to 9.8% with placebo (difference, 48.0%; 95% CI, 35.3 to 60.8; p < 0.001).

More participants receiving HSK31679 achieved ≥ 30% reduction in MRI-PDFF at week 52 (52.5% and 53.3% vs 25.0%; both p < 0.01).

A greater proportion of patients treated with pemvidutide achieved a ≥ 30% reduction in LSM than placebo [1.2 mg (61.1%; p < 0.0001), 1.8 mg (63.9%; p < 0.0001), placebo (21.2%)].

The most frequent AEs with CAM2029 were diarrhoea (68.1%), injection site pruritus (42.6%), injection site pain (40.4%) and abdominal pain (36.2%).

Among patients with <5% bodyweight loss, those treated with DD01 achieved a 37.4% reduction in MRI-PDFF (95% CI, -72.9, -1.9), versus an increase of 1.6% (-30.4, 33.6) in placebo subjects.

Cumulative composite response rates reached 39.6% (original linafexor) and 30.8% (crossover).

Resolution of MASH with no worsening of fibrosis was observed in 27.7% of 1,500 mg NCA patients vs. 19.0% of placebo patients (p=0.18), while improvement of fibrosis with no worsening of MASH was reported for 18.1% of 1,500 mg NCA patients vs. 20.6% of placebo patients.

After 48 weeks, HDV RNA decreased by ≥2 log10 from baseline in 97% (31/32) of participants receiving tobevibart+elebsiran Q4W and HDV RNA target not detected (TND) was achieved by 66% (21/32) of participants.

A greater proportion of pts in the efimosfermin 225 mg and 300 mg groups achieved a response (8% [1/12] and 7% [5/68], respectively) compared with placebo (3%; 1/40).

In the D+Q group, 14/17 participants reported adverse events (AE) compared to 6 with placebo.